BioCentury
ARTICLE | Emerging Company Profile

Milo: Dismissing dystrophin

Milo using follistatin, not dystrophin, in muscular dystrophy gene therapy

August 6, 2012 7:00 AM UTC

Milo Biotechnology LLC is developing a gene therapy to treat muscular dystrophy that up-regulates follistatin, a protein already present in the body, which could avoid immune reactions that have scuttled previous gene therapies.

The company's only candidate is AAV1-FS, which uses an adeno-associated virus vector to deliver follistatin. It is in Phase I/II testing for Becker muscular dystrophy and inclusion body myositis...